Phase 3 Readout~month

Phase 3 Topline: A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and

Indication
Non-Alcoholic Fatty Liver Disease

Other upcoming events for MDGL

Phase 3 ReadoutPhase 3 Topline: A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on L
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and — MDGL Phase 3 Readout | BioSniper